当前位置: 首页 >> 检索结果
3901. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis.
作者: Derk C F Klatte.;Bas Boekestijn.;Anke M Onnekink.;Friedo W Dekker.;Lydia G van der Geest.;Martin N J M Wasser.;Shirin Feshtali.;J Sven D Mieog.;Saskia A C Luelmo.;Hans Morreau.;Thomas P Potjer.;Akin Inderson.;Jurjen J Boonstra.;Hans F A Vasen.;Jeanin E van Hooft.;Bert A Bonsing.;Monique E van Leerdam.; .
来源: Gastroenterology. 2023年164卷7期1223-1231.e4页
Recent pancreatic cancer surveillance programs of high-risk individuals have reported improved outcomes. This study assessed to what extent outcomes of pancreatic ductal adenocarcinoma (PDAC) in patients with a CDKN2A/p16 pathogenic variant diagnosed under surveillance are better as compared with patients with PDAC diagnosed outside surveillance.
3906. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis.
作者: Sintayehu Fekadu.;Hizkel Engiso.;Sisay Seyfe.;Hisashi Iizasa.;Ashebir Godebo.;Serawit Deyno.;Hironori Yoshiyama.
来源: BMC Gastroenterol. 2023年23卷1期55页
The effectiveness of Helicobacter pylori (H. pylori) eradication depends on the treatment protocol. This study investigates the H. pylori eradication rate in Africa using the best available evidence from databases.
3907. A novel nomogram for identifying candidates for adjuvant chemotherapy in patients with stage IB gastric adenocarcinoma.
作者: Yangyang Xie.;Xue Song.;Danwei Du.;Haimin Jin.;Xiaowen Li.;Zhongkai Ni.;Hai Huang.
来源: BMC Gastroenterol. 2023年23卷1期54页
The purpose of this research was to construct a novel predictive nomogram to identify specific stage IB gastric adenocarcinoma (GAC) populations who could benefit from postoperative adjuvant chemotherapy (ACT).
3909. Stiffness Restricts the Stemness of the Intestinal Stem Cells and Skews Their Differentiation Toward Goblet Cells.
作者: Shijie He.;Peng Lei.;Wenying Kang.;Priscilla Cheung.;Tao Xu.;Miyeko Mana.;Chan Young Park.;Hongyan Wang.;Shinya Imada.;Jacquelyn O Russell.;Jianxun Wang.;Ruizhi Wang.;Ziheng Zhou.;Kashish Chetal.;Eric Stas.;Vidisha Mohad.;Peter Bruun-Rasmussen.;Ruslan I Sadreyev.;Richard A Hodin.;Yanhang Zhang.;David T Breault.;Fernando D Camargo.;Ömer H Yilmaz.;Jeffrey J Fredberg.;Nima Saeidi.
来源: Gastroenterology. 2023年164卷7期1137-1151.e15页
Fibrosis and tissue stiffening are hallmarks of inflammatory bowel disease (IBD). We have hypothesized that the increased stiffness directly contributes to the dysregulation of the epithelial cell homeostasis in IBD. Here, we aim to determine the impact of tissue stiffening on the fate and function of the intestinal stem cells (ISCs).
3910. Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis.
作者: Marietta Iacucci.;Tommaso Lorenzo Parigi.;Rocio Del Amor.;Pablo Meseguer.;Giulio Mandelli.;Anna Bozzola.;Alina Bazarova.;Pradeep Bhandari.;Raf Bisschops.;Silvio Danese.;Gert De Hertogh.;Jose G Ferraz.;Martin Goetz.;Enrico Grisan.;Xianyong Gui.;Bu Hayee.;Ralf Kiesslich.;Mark Lazarev.;Remo Panaccione.;Adolfo Parra-Blanco.;Luca Pastorelli.;Timo Rath.;Elin S Røyset.;Gian Eugenio Tontini.;Michael Vieth.;Davide Zardo.;Subrata Ghosh.;Valery Naranjo.;Vincenzo Villanacci.
来源: Gastroenterology. 2023年164卷7期1180-1188.e2页
Microscopic inflammation has significant prognostic value in ulcerative colitis (UC); however, its assessment is complex with high interobserver variability. We aimed to develop and validate an artificial intelligence (AI) computer-aided diagnosis system to evaluate UC biopsies and predict prognosis.
3914. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
作者: Chenhao Zhou.;Jialei Weng.;Chunxiao Liu.;Shaoqing Liu.;Zhiqiu Hu.;Xiaoli Xie.;Dongmei Gao.;Qiang Zhou.;Jialei Sun.;Ruchen Xu.;Hui Li.;Yinghao Shen.;Yong Yi.;Yi Shi.;Xia Sheng.;Qiongzhu Dong.;Mien-Chie Hung.;Ning Ren.
来源: Gastroenterology. 2023年164卷7期1261-1278页
The therapeutic effect of immune checkpoint inhibitors (ICIs) is poor in hepatocellular carcinoma (HCC) and varies greatly among individuals. Schlafen (SLFN) family members have important functions in immunity and oncology, but their roles in cancer immunobiology remain unclear. We aimed to investigate the role of the SLFN family in immune responses against HCC.
3915. Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome.
作者: Giulia Fiorini.;Ilaria M Saracino.;Matteo Pavoni.;Bruno Nipote.;Raffaele Colucci.;Pietro Capone.;Angela Sannino.;Fabrizio Forte.;Emiliano DE Vergori.;Mario Brancaccio.;Maurizio Cesareo.;Giovanni Casella.;Gaetano C Morreale.;Leonilde Bonfrate.;Piero Portincasa.;Massimo Vincenzi.;Carmelo Cottone.;Vittorio M Ormando.;Natale Scalise.;Paulin F Lawson.;Osvaldo Burattini.;Amedeo Montale.;Francesco Luzza.;Mauro Rossi.;Riccardo Vanni.;Rosamaria Bozzi.;Giuseppina Vincoli.;Nicoletta Stefani.;Claudio Borghi.;Dino Vaira.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期123-127页
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders. IBS is characterized by recurrent chronic abdominal pain and altered bowel habits in the absence of organic damage. Although there are reviews and guidelines for treating IBS, the complexity and diversity of IBS presentation make treatment difficult. Treatment of IBS focuses on relieving symptoms as mild signs and symptoms can often be controlled by managing stress and by making changes in diet and lifestyle. The use of nutraceutical compounds has been advocated as a possible alternative treatment in patients with IBS. COLONIR® (Omega Pharma Srl, Milan, Italy) may be an alternative or adjuvant treatment in patients with gastrointestinal symptoms. This study aimed to evaluate the effect of this new nutraceutical formulation in inducing symptoms remission and improve gastrointestinal habits.
3916. Intestinal fat absorption shifting: polyglucosamine biopolymer controls lipids and weight and reduces the progression of subclinical atherosclerosis.
作者: Gianni Belcaro.;Umberto Cornelli.;Morio Hosoi.;David Cox.;Mark Dugall.;Maria R Cesarone.;Andrea Ledda.;Valeria Scipione.;Claudia Scipione.;Beatrice Feragalli.;Roberto Cotellese.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期114-122页
Intestinal fat absorption shifting (IFAS) can be obtained in hyperlipidemic subjects with polyglucosamine biopolymer (BP) able to segregate most metabolic fats in the gut, making them unavailable for intestinal interaction (shift). The aim of this study was to evaluate the effects of a SM (standard management) for hyperlipidemia in asymptomatic subjects for primary cardiovascular prevention focusing on arterial wall morphology (IMT thickness) in comparison to SM associated to the administration of the BP.
3917. Treatment of portal vein thrombosis in cirrhosis: a multicenter real life cοhort study.
作者: Aikaterini Mantaka.;Nikolaos Gatselis.;Christos K Triantos.;Ulrich Thalheimer.;Gioacchino Leandro.;Kalliopi Zachou.;Christos Konstantakis.;Asterios Saitis.;Konstantinos Thomopoulos.;Elias A Kouroumalis.;George N Dalekos.;Dimitrios N Samonakis.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期107-113页
Portal vein thrombosis (PVT) is a common complication of cirrhosis and can be a cause or consequence of liver disease progression. It is unclear whether PVT treatment is affecting clinical outcomes in cirrhotics.
3918. Health-related quality of life and symptoms in autoimmune liver diseases.
作者: Maciej K Janik.;Ewa Wunsch.;Piotr Milkiewicz.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期50-60页
Assessment of Health-Related Quality of Life (HRQoL) has emerged as an important tool in the evaluation of both the well-being of patients and the results of their clinical management. Over the years, a large number of questionnaires focusing on various aspects of quality of life have been developed. They are frequently divided into generic questionnaires, which can be used under various conditions, disease-specific and symptom-specific questionnaires. Autoimmune liver diseases, such as autoimmune hepatitis, primary sclerosing cholangitis, or primary biliary cirrhosis, comprise a group of rare liver conditions (i.e. affecting fewer than 5 in 10,000 people in the general population). Unfortunately, HRQoL has not been well-studied in this group of patients. In this review, we comprehensively summarize the data available in the literature on HRQoL in these conditions, emphasizing the important role that quality of life plays in the successful management of such patients.
3920. Novelties on non-invasive biomarkers for the assessment of intestinal permeability and gut barrier integrity in patients with inflammatory bowel diseases.
作者: Gian P Caviglia.;Davide G Ribaldone.;Sharmila Fagoonee.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期1-3页 |